Also found in: Medical.
PPARPeroxisome Proliferator Activated Receptor
PPARPikes Peak Association of Realtors (Colorado Springs, CO)
PPARPaw Prints Animal Rescue (Garner, NC)
PPARPharmaceutical Process Analytics Roundtable
PPARPeripheral Pulse Amplitude Response (physiology)
PPARPhenomenon of Predominant Activation of Relaxation
References in periodicals archive ?
PPARs can be activated and cooperate with thyroid hormone and retinoid X receptors by the formation of a heterodimer complex for transcriptional regulation of target genes (Wahli et al.
The LBE treated cells showed a specific increase in expression of PPAR target gene expression, including fatty acid binding protein 4, fatty acid transport protein 4, CD36 molecule, pyruvate dehydrogenase kinase 4, liver X receptor alpha and lipogenic stearoyl-CoA desaturase.
These results also provide a new rationale for developing therapeutics that could block PPAR delta to treat inflammatory bowel disease and colorectal cancer," he said.
We will focus on the premise that PPAR activation is indeed anti-inflammatory and has therapeutic benefit.
These beneficial effects on glucose and lipids were observed without causing the weight gain which has been seen with other PPAR agonists.
Consistent with the low level of endogenous expression of PPARs in the human hepatocyte, the PPAR[alpha] inhibitor had minimal effects on basal and CLA-stimulated gene expression in cultured HepG2 cells.
Each PPAR is subject to a peer review process and OED management approval.
Following standard OED procedures, copies of the draft PPAR will be sent to the relevant government officials and agencies for their review and comments.
It is our hypothesis that decreasing the amount of free fatty acids, which are PPAR [gamma] agonists, may result in a decrease in UCP2 and PPAR [gamma] expression in murine hepatocytes.
with overexpresssion of HER2/neu or overexpression of epidermal growth factor receptor, are treated with strongly binding PPAR gamma ligands, and patients affected with cancer associated with overexpression of at least one member of the class I family of receptor tyrosine kinases selected from the group consisting of HER-2/neu and epidermal growth factor rector, comprising administering to said patient a therapeutically effective amount of a ligand of peroxisome proliferator-activated receptor gamma (PPAR gamma) which has a pKi of at least 4.